Safety concerns about CCR5 as an antiviral target

Current Opinion in HIV and AIDS

Volumn 4, Issue 2, 2009, Pages 131-135

  Telenti, Amalio ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

CCR5 antagonists; CCR5 32; Maraviroc; Vicriviroc

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; GAMMA INTERFERON; PLERIXAFOR; RIBAVIRIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; IMMUNOLOGIC FACTOR;

ALLELE; CD4+ T LYMPHOCYTE; CERCOCEBUS; CHLAMYDIA TRACHOMATIS; COHORT ANALYSIS; CRYPTOCOCCUS NEOFORMANS; DRUG SAFETY; DRUG TARGETING; GENE DELETION; HEPATITIS B; HEPATITIS C; HERPES SIMPLEX VIRUS; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INFECTION SENSITIVITY; LISTERIA; LOSS OF FUNCTION MUTATION; LYMPHOCYTE MIGRATION; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER CELL; NONHUMAN; PLASMODIUM; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TICK BORNE ENCEPHALITIS; TICK BORNE ENCEPHALITIS FLAVIVIRUS; TOXOPLASMA GONDII; TRYPANOSOMA CRUZI; VIRUS ENCEPHALITIS; WEST NILE FLAVIVIRUS; ANIMAL; BACTERIAL INFECTION; DRUG ANTAGONISM; IMMUNOLOGY; MOUSE; PROTOZOAL INFECTION; VIRUS INFECTION;

ANIMALS; ANTI-HIV AGENTS; BACTERIAL INFECTIONS; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; IMMUNOLOGIC FACTORS; MICE; PROTOZOAN INFECTIONS; RECEPTORS, CCR5; VIRUS DISEASES;

EID: 65549149088     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283223d76     Document Type: Review

References (46)

1. Lederman MM, Penn-Nicholson A, Cho M, Mosier D. Biology of CCR5 and its role in HIV infection and treatment. J Am Med Assoc 2006; 296:815-826. (Pubitemid 44223105)
2. Wong MM, Fish EN. Chemokines: attractive mediators of the immune response. Semin Immunol 2003; 15:5-14.
3. Khan IA, Thomas SY, Moretto MM, et al. CCR5 is essential for NK cell trafficking and host survival following Toxoplasma gondii infection. PLoS Pathog 2006; 2:e49.
4. Glass WG, Lim JK, Cholera R, et al. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med 2005; 202:1087-1098. (Pubitemid 41464502)
5. Floto RA, MacAry PA, Boname JM, et al. Dendritic cell stimulation by mycobacterial Hsp70 is mediated through CCR5. Science 2006; 314:454-458.
6. Ank N, Petersen K, Malmgaard L, et al. Age-dependent role for CCR5 in antiviral host defense against herpes simplex virus type 2. J Virol 2005; 79:9831-9841. (Pubitemid 41022325)
7. Machado FS, Koyama NS, Carregaro V, et al. CCR5 plays a critical role in the development of myocarditis and host protection in mice infected with Trypanosoma cruzi. J Infect Dis 2005; 191:627-636. (Pubitemid 40216680)
8. Belnoue E, Kayibanda M, Deschemin JC, et al. CCR5 deficiency decreases susceptibility to experimental cerebral malaria. Blood 2003; 101:4253-4259. (Pubitemid 36857785)
9. Huffnagle GB, McNeil LK, McDonald RA, et al. Cutting edge: role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans. J Immunol 1999; 163:4642-4646.
10. Barr EL, Ouburg S, Igietseme JU, et al. Host inflammatory response and development of complications of Chlamydia trachomatis genital infection in CCR5-deficient mice and subfertile women with the CCR5delta32 gene deletion. J Microbiol Immunol Infect 2005; 38:244-254. (Pubitemid 41297209)
11. Kindberg E, Mickiene A, Ax C, et al. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis 2008; 197:266-269. Human susceptibility to a second flavivirus in CCR5D32 individuals identified in Lithuania. (Pubitemid 351263446)
12. Thio CL, Astemborski J, Bashirova A, et al. Genetic protection against HBV conferred by CCR5{Delta}32: evidence that CCR5 contributes to viral persistence. J Virol 2007; 81:441-445.
13. Zhou Y, Kurihara T, Ryseck RP, et al. Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J Immunol 1998; 160:4018-4025. (Pubitemid 28176111)
14. Este JA, Telenti A. HIV entry inhibitors. Lancet 2007; 370:81-88.
15. Gardam MA, Keystone EC, Menzies R, et al. Antitumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3:148-155. (Pubitemid 36278124)
16. Vazquez-Salat N, Yuhki N, Beck T, et al. Gene conversion between mammalian CCR2 and CCR5 chemokine receptor genes: a potential mechanism for receptor dimerization. Genomics 2007; 90:213-224. (Pubitemid 47030810)
17. Lio P, Vannucci M. Investigating the evolution and structure of chemokine receptors. Gene 2003; 317:29-37. (Pubitemid 37356915)
18. Esteves PJ, Abrantes J, van der LW. Extensive gene conversion between CCR2 and CCR5 in domestic cat (Felis catus). Int J Immunogenet 2007; 34:321-324. (Pubitemid 47383400)
19. Perelygin AA, Zharkikh AA, Astakhova NM, et al. Concerted evolution of vertebrate CCR2 and CCR5 genes and the origin of a recombinant equine CCR5/2 gene. J Hered 2008; 99:500-511.
20. Novembre J, Galvani AP, Slatkin M. The geographic spread of the CCR5 Delta32 HIV-resistance allele. PLoS Biol 2005; 3:e339. (Pubitemid 41652447)
21. Sabeti PC, Walsh E, Schaffner SF, et al. The case for selection at CCR5-Delta32. PLoS Biol 2005; 3:e378.
22. Hummel S, Schmidt D, Kremeyer B, et al. Detection of the CCR5-Delta32 HIV resistance gene in Bronze Age skeletons. Genes Immun 2005; 6:371-374. (Pubitemid 40903412)
23. Ribeiro IP, Schrago CG, Soares EA, et al. CCR5 chemokine receptor gene evolution in New World monkeys (Platyrrhini, Primates): implication on resistance to lentiviruses. Infect Genet Evol 2005; 5:271-280.
24. Chen Z, Kwon D, Jin Z, et al. Natural infection of a homozygous delta24 CCR5 red-capped mangabey with an R2b-tropic simian immunodeficiency virus. J Exp Med 1998; 188:2057-2065. (Pubitemid 28562522)
25. Nansen A, Christensen JP, Andreasen SO, et al. The role of CC chemokine receptor 5 in antiviral immunity. Blood 2002; 99:1237-1245. (Pubitemid 34547076)
26. Ng-Cashin J, Kuhns JJ, Burkett SE, et al. Host absence of CCR5 potentiates dendritic cell vaccination. J Immunol 2003; 170:4201-4208. (Pubitemid 36428186)
27. McCandless EE, Zhang B, Diamond MS, Klein RS. CXCR4 antagonism increases T cell trafficking in the central nervous system and improves survival from West Nile virus encephalitis. Proc Natl Acad Sci U S A 2008; 105:11270-11275.
28. Rahbar R, Murooka TT, Hinek AA, et al. Vaccinia virus activation of CCR5 invokes tyrosine phosphorylation signaling events that support virus replication. J Virol 2006; 80:7245-7259. (Pubitemid 44025221)
29. Whittall T, Wang Y, Younson J, et al. Interaction between the CCR5 chemokine receptors and microbial HSP70. Eur J Immunol 2006; 36:2304-2314. (Pubitemid 44420587)
30. Hardison JL, Wrightsman RA, Carpenter PM, et al. The CC chemokine receptor 5 is important in control of parasite replication and acute cardiac inflammation following infection with Trypanosoma cruzi. Infect Immun 2006; 74:135-143. (Pubitemid 43023067)
31. Lim JK, Glass WG, McDermott DH, Murphy PM. CCR5: no longer a 'good for nothing' gene-chemokine control of West Nile virus infection. Trends Immunol 2006; 27:308-312.
32. Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006; 203:35-40. (Pubitemid 43139642)
33. Lim JK, Louie CY, Glaser C, et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis 2008; 197:262-265. The stronger evidence till date of the clinical consequences of CCR5 deletion in the general population. (Pubitemid 351263445)
34. Guarner J, Shieh WJ, Hunter S, et al. Clinicopathologic study and laboratory diagnosis of 23 cases with West Nile virus encephalomyelitis. Hum Pathol 2004; 35:983-990. (Pubitemid 39037181)
35. Jamison SC, Michaels SR, Ratard R, et al. A 41-year-old HIV-positive man with acute onset of quadriplegia after West Nile virus infection. South Med J 2007; 100:1051-1053. (Pubitemid 47537894)
36. Torno M, Vollmer M, Beck CK. West Nile virus infection presenting as acute flaccid paralysis in an HIV-infected patient: a case report and review of the literature. Neurology 2007; 68:E5-E7. (Pubitemid 46263198)
37. Szilak I, Minamoto GY. West Nile viral encephalitis in an HIV-positive woman in New York. N Engl J Med 2000; 342:59-60. (Pubitemid 30020665)
38. Wheeler J, McHale M, Jackson V, Penny M. Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: experience in a drug development programme for maraviroc. Antivir Ther 2007; 12:233-245. An effort by the pharmaceutical industry to assess the potential risk of CCR5 modulation in a population infected (or co-infected) with HCV or HBV, and the risk for selected autoimmune disorders. (Pubitemid 46569908)
39. Goulding C, McManus R, Murphy A, et al. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut 2005; 54:1157-1161. (Pubitemid 41025913)
40. Moreno C, Gustot T, Nicaise C, et al. CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice. Hepatology 2005; 42:854-862. (Pubitemid 41401123)
41. Prahalad S. Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis. Genes Immun 2006; 7:264-268.
42. Fischereder M, Luckow B, Hocher B, et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001; 357:1758-1761.
43. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007; 196:304-312. (Pubitemid 47047471)
44. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-1441.
45. Fatkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359:1442-1455.
46. Dolin R. A new class of anti-HIV therapy and new challenges. N Engl J Med 2008; 359:1509-1511.